Objectives of the project 

The overarching goal of the network is to establish new tools, technologies and expertise for accelerating the development of advanced human induced pluripotent stem cell (iPSC)-based therapies. The project also aims at overcoming scientific, regulatory and in particular safety hurdles, necessary to initiate a first in-man (FIM) clinical trial for the therapeutic administration of allogeneic, human leukocyte antigen (HLA)-homozygous iPSC-cardiomyocyte aggregates, for improving the function of damaged hearts.

Both academic and industrial research communities will be able to use the results of the project to advance their R&D efforts in cell therapies towards the clinic. New tolls, logistic solutions and AI powered technologies as an outcome of the project will strengthen Europe’s leadership in healthcare technology development, including the ability to scale up and bring iPSC-based therapies to the patient. Citizens will benefit more rapid translation of cell therapy research to the clinic for better patient outcome and well-being. This in mind, the realization of a therapy for heart disease is particularly important since very few alternatives currently exist for heart failure patients. Finally, the project outcome will facilitate decision-making by authorities and clinicians in a secure and ethical manner, for respecting individual integrity and underpinned with public acceptance and trust.